AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Deutsche Bank Lowers GoodRx Price Target to $6, Maintains Hold Rating
ByAinvest
Monday, Aug 11, 2025 4:06 pm ET1min read
Deutsche Bank analyst George Hill has lowered the price target for GoodRx (GDRX) to $6 from $8 and maintains a Hold rating on the shares. The decision comes after evaluating various factors, including the company's financial performance and market trends.
Deutsche Bank analyst George Hill has revised the price target for GoodRx Holdings (NASDAQ: GDRX) to $6 from $8, maintaining a Hold rating on the shares. This adjustment comes after a comprehensive evaluation of the company's financial performance and market trends.GoodRx Holdings reported its second-quarter 2025 earnings, with revenue of $203.1 million, a 1.2% increase from the same period last year. Net income was $12.8 million, up 92% from the previous year. However, the earnings per share (EPS) of $0.036 missed analyst estimates by 1.4% [1]. The company's shares have seen significant volatility, with a trading range between $3.40 and $3.55 during the earnings call [2].
The price target reduction reflects the analyst's assessment of ongoing risks and challenges in the healthcare sector. UBS recently lowered its price target to $4.25 due to the impact of Rite Aid's bankruptcy and volume challenges with one of GoodRx's pharmacy benefit manager (PBM) partners [3]. Morgan Stanley also lowered its price target to $5.00, citing retail challenges and the impact of a major retail pharmacy's bankruptcy [4].
Despite these challenges, GoodRx Holdings maintains a strong gross profit margin of 93.84% and has an active share repurchase program, buying back 10.2 million shares for $46.4 million in the second quarter [4]. The company's Pharma Manufacturing Solutions business generated $35 million in revenue, up 32% year-over-year, driven by continued market penetration and growth in consumer direct pricing [4].
The recent earnings report and market trends indicate that investors should closely monitor GoodRx's progress and any developments that could impact its stock price.
References:
[1] https://finance.yahoo.com/news/goodrx-holdings-second-quarter-2025-124816295.html
[2] https://site.financialmodelingprep.com/market-news/goodrx-holdings-price-target-deutsche-bank-optimism
[3] https://www.investing.com/news/analyst-ratings/goodrx-stock-price-target-lowered-to-425-from-525-at-ubs-93CH-4183315
[4] https://ca.investing.com/news/analyst-ratings/goodrx-stock-falls-as-morgan-stanley-cuts-price-target-on-retail-challenges-93CH-4147117
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet